Nautilus Biotechnology, Inc.
NAUT Nasdaq· Laboratory Analytical Instruments
Last close · Oct 23, 2026
$3.24
KIRA · Stoqly’s AI analyst, in plain words
- Nautilus Biotechnology, Inc. lost $59.0M in fiscal 2025.
- Free cash flow was −$52.0M in fiscal 2025, — of revenue.
Market cap
$412M
P/E
—
Revenue
—
Net income
−$59.0M
Free cash flow
−$52.0M
Operating margin
—
Nautilus Biotechnology, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$59.0M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Nautilus Biotechnology, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Nautilus Biotechnology, Inc.
- CIK
- 0001808805
Nautilus Biotechnology, Inc. · NAUT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$50.3M | −$57.9M | −$63.7M | −$70.8M | −$59.0M |
| Diluted EPS | −$0.60 | −$0.46 | −$0.51 | −$0.56 | −$0.47 |
| Cash | |||||
| Cash from operations | −$39.2M | −$45.8M | −$51.7M | −$59.1M | −$50.7M |
| Capital expenditure | $2.3M | $2.3M | $2.4M | $2.1M | $1.3M |
| Free cash flow | −$41.5M | −$48.1M | −$54.2M | −$61.3M | −$52.0M |
| Share count change | 190.4% | 47.5% | 0.3% | 0.4% | 0.7% |
| Debt and strength | |||||
| Cash and short-term investments | $346M | $184M | $173M | $130M | $103M |
| Shareholders' equity | $364M | $315M | $265M | $209M | $157M |
| Current ratio | 60.1x | 27.6x | 19.4x | 17.4x | 13.3x |
| Returns and quality | |||||
| Return on equity | −30.1% | −17.1% | −21.9% | −29.9% | −32.3% |
| Return on tangible equity | −13.8% | −18.4% | −24.0% | −33.9% | −37.6% |
Insiders bought, 12 months
$0.1M
2 insiders
Insiders sold, 12 months
$11.8M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Nautilus Biotechnology, Inc. · NAUT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.24 a share, the company is worth $412M.
Source: SEC EDGAR XBRL filings (CIK 0001808805). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.